AbbVie Becomes Another Big Pharma To Enter Obesity Treatment Race

On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.“Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,” said Robert Michael, CEO of AbbVie.Also Read: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Sh ...